Reported Sunday, Celldex Presents Phase 2 Data Showing Up To 64% Of Barzolvolimab-Treated CSU Patients Remained Angioedema-Free Seven Months After Last Dose At EAACI Annual Meeting
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. CLDX | 0.00 |
- Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
- Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
- Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
- Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026